Horizon Pharma plc (HZNP) : On Monday, The money flowed into the Horizon Pharma plc (HZNP) stock with an uptick to downtick ratio was recorded at 1.11. Transactions worth $10.97 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $9.88 million. The total money flow into the stock was $1.08 million. The block trades reveal a bullish bias with an up-down ratio of 1.2. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $2.42 million of block transactions on upticks. The value of block trades on downticks was $2 million, indicating lower selling interest. The total money flow in block trades was $0.41 million. In terms of price action, Horizon Pharma plc (HZNP) traded down $0.06 during the session at $23.13. Compared to the previous days closing, the stock was down only by -0.26%. For the week, the stock is 15.07%, over previous weeks closing.
Shares of Horizon Pharma plc rose by 10.26% in the last five trading days and 20.87% for the last 4 weeks. Horizon Pharma plc is up 55.62% in the last 3-month period. Year-to-Date the stock performance stands at 6.65%.
Horizon Pharma plc (NASDAQ:HZNP): The stock opened at $23.30 on Monday but the bulls could not build on the opening and the stock topped out at $23.44 for the day. The stock traded down to $22.78 during the day, due to lack of any buying support eventually closed down at $23.11 with a loss of -0.34% for the day. The stock had closed at $23.19 on the previous day. The total traded volume was 2,957,439 shares.
In a related news, The Securities and Exchange Commission has divulged that Sherman Jeffrey W, officer (EVP and Chief Medical Officer) of Horizon Pharma Plc, had unloaded 2,900 shares at an average price of $20 in a transaction dated on August 2, 2016. The total value of the transaction was worth $58,000.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.